284 related articles for article (PubMed ID: 22122181)
1. Role of pharmacogenomics in the management of traditional and novel oral anticoagulants.
Cavallari LH; Shin J; Perera MA
Pharmacotherapy; 2011 Dec; 31(12):1192-207. PubMed ID: 22122181
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of oral anticoagulants: a basis for dose individualization.
Stehle S; Kirchheiner J; Lazar A; Fuhr U
Clin Pharmacokinet; 2008; 47(9):565-94. PubMed ID: 18698879
[TBL] [Abstract][Full Text] [Related]
3. Warfarin pharmacogenetics.
Limdi NA; Veenstra DL
Pharmacotherapy; 2008 Sep; 28(9):1084-97. PubMed ID: 18752379
[TBL] [Abstract][Full Text] [Related]
4. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
[TBL] [Abstract][Full Text] [Related]
5. Warfarin pharmacogenomics.
Cavallari LH; Limdi NA
Curr Opin Mol Ther; 2009 Jun; 11(3):243-51. PubMed ID: 19479657
[TBL] [Abstract][Full Text] [Related]
6. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
[TBL] [Abstract][Full Text] [Related]
7. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.
Johnson JA; Gong L; Whirl-Carrillo M; Gage BF; Scott SA; Stein CM; Anderson JL; Kimmel SE; Lee MT; Pirmohamed M; Wadelius M; Klein TE; Altman RB;
Clin Pharmacol Ther; 2011 Oct; 90(4):625-9. PubMed ID: 21900891
[TBL] [Abstract][Full Text] [Related]
8. Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation.
Cho HJ; On YK; Bang OY; Kim JW; Huh W; Ko JW; Kim JS; Lee SY
Clin Ther; 2011 Oct; 33(10):1371-80. PubMed ID: 21981797
[TBL] [Abstract][Full Text] [Related]
9. Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin.
Schwartz JB; Kane L; Moore K; Wu AH
J Am Med Dir Assoc; 2011 Nov; 12(9):633-8. PubMed ID: 21450231
[TBL] [Abstract][Full Text] [Related]
10. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
[TBL] [Abstract][Full Text] [Related]
11. Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice.
Becquemont L
Eur J Clin Pharmacol; 2008 Oct; 64(10):953-60. PubMed ID: 18758764
[TBL] [Abstract][Full Text] [Related]
12. Warfarin dosing and the promise of pharmacogenomics.
Dumas TE; Hawke RL; Lee CR
Curr Clin Pharmacol; 2007 Jan; 2(1):11-21. PubMed ID: 18690851
[TBL] [Abstract][Full Text] [Related]
13. Warfarin pharmacogenetics: does more accurate dosing benefit patients?
Eby C
Semin Thromb Hemost; 2012 Oct; 38(7):661-6. PubMed ID: 23047421
[TBL] [Abstract][Full Text] [Related]
14. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
[TBL] [Abstract][Full Text] [Related]
15. Role of warfarin pharmacogenetic testing in clinical practice.
Tan GM; Wu E; Lam YY; Yan BP
Pharmacogenomics; 2010 Mar; 11(3):439-48. PubMed ID: 20402581
[TBL] [Abstract][Full Text] [Related]
16. Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis.
Takeuchi M; Kobayashi T; Brandão LR; Ito S
Syst Rev; 2016 Jun; 5(1):105. PubMed ID: 27334984
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of warfarin.
Kamali F; Wynne H
Annu Rev Med; 2010; 61():63-75. PubMed ID: 19686083
[TBL] [Abstract][Full Text] [Related]
18. [Warfarin resistance and related pharmacogenetic information].
Takahashi H
Brain Nerve; 2008 Nov; 60(11):1365-71. PubMed ID: 19069171
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetics of coumarinic oral anticoagulants.
Manolopoulos VG; Ragia G; Tavridou A
Pharmacogenomics; 2010 Apr; 11(4):493-6. PubMed ID: 20350128
[TBL] [Abstract][Full Text] [Related]
20. Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.
Daly AK
Arch Toxicol; 2013 Mar; 87(3):407-20. PubMed ID: 23376975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
